909854-16-6 Usage
General Description
3-Ethoxypyridin-2-ol is a chemical compound with the molecular formula C7H9NO2. It is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs and pharmaceuticals. It is a clear, colorless liquid with a mild, pleasant odor. 3-Ethoxypyridin-2-ol is known for its ability to act as a chelating agent, meaning it can bind to metal ions, which makes it useful in various industrial processes and as a potential therapeutic agent in medicine. It is also used in the production of insecticides and fungicides due to its ability to inhibit enzyme activity. Overall, 3-Ethoxypyridin-2-ol has a range of industrial and pharmaceutical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 909854-16-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,9,8,5 and 4 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 909854-16:
(8*9)+(7*0)+(6*9)+(5*8)+(4*5)+(3*4)+(2*1)+(1*6)=206
206 % 10 = 6
So 909854-16-6 is a valid CAS Registry Number.
909854-16-6Relevant articles and documents
NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
-
Paragraph 0211-0212, (2020/01/22)
Disclosed are a novel isoindoline derivative, a pharmaceutical composition and use thereof. The compound of formula I, or the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotopic compound, metabolite or prodrug thereof disclosed in the invention can regulate the generation and/or activity of PDE4 and/or TNF-α so as to effectively treat cancer and inflammatory diseases.
Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
-
Page/Page column 35-36, (2010/11/23)
This invention is concerned with compounds of the formula wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
